Aaron G.l. Fletcher - 22 Nov 2022 Form 4 Insider Report for TFF Pharmaceuticals, Inc.

Role: Director
Signature: /s/ Aaron G.L. Fletcher, by Kirk Allen Coleman, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 22 Nov 2022
Net transactions value: +$49,990
Form type: 4
Filing time: 23 Nov 2022, 06:59:10 UTC
Previous filing: 17 Nov 2022
Next filing: 29 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TFFP	Common Stock	Purchase	$49,990	+43,470	+43%	$1.15	143,470	22 Nov 2022	Direct	F3
holding	TFFP	Common Stock						109,600	22 Nov 2022	See footnote	F1
holding	TFFP	Common Stock						542,000	22 Nov 2022	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TFFP	Common Stock Purchase Warrants	Purchase	$0	+21,735		$0.000000	21,735	22 Nov 2022	Common Stock	21,735	$1.29	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund II, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund II, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.
F2	The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.
F3	The reported shares were purchased in a private transaction from TFF Pharmaceuticals, Inc. at a price of $1.15.